×
About 20,084 results
Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHES...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177099
Journal of the American College of Radiology : JACR; Mazzone PJ, Gould MK et. al.

Jun 2nd, 2020 - The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendations for lung cancer screening and lung nodule evaluation. Consensus statements were developed to guide clinicians managing lung cancer screening prog...

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Early local therapy fails to extend survival in metastatic breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{fce1cd33-c5fd-4bf8-8336-97281967a80c}/early-local-therapy-fails-to-extend-survival-in-metastatic-breast-cancer-subset

May 31st, 2020 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/onclive-tv/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020 - Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL
https://www.onclive.com/onclive-tv/dr-wang-on-correlative-data-from-the-zuma2-trial-in-mcl

May 31st, 2020 - Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer
https://www.onclive.com/onclive-tv/dr-poveda-on-the-results-of-the-solo2-trial-in-ovarian-cancer

May 31st, 2020 - Andres Poveda, MD, Initia Oncology, Hospital Quironsalud, in Valencia, Spain, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Add-On Tucatinib Ups Survival in Breast Cancer With Brain Mets
https://www.medpagetoday.com/meetingcoverage/asco/86787

May 31st, 2020 - Adding tucatinib (Tukysa) to a trastuzumab-capecitabine (Herceptin-Xeloda) regimen significantly improved central nervous system (CNS) outcomes versus placebo plus trastuzumab-capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases at baseline, researchers reported.

VRd Still Reigns in Newly Diagnosed Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86786

May 31st, 2020 - share to facebook share to twitter share to linkedin email article The combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, or VRd, successfully fended off a direct challenge to its position as standard of care in newly diagnosed multiple myeloma.

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC
https://www.onclive.com/onclive-tv/dr-herbst-on-the-benefit-of-adjuvant-osimertinib-in-egfrmutant-nsclc

May 31st, 2020 - Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology; chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital; and associate cancer center director for Translational Research at Yale Cancer Center, discusses the benefit of adjuvant osimertinib (Tagrisso) demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer (NSCLC)...

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/dr-usmani-on-activity-of-teclistamab-in-relapsed-refractory-multiple-myeloma

May 31st, 2020 - Saad Usmani, MD, chief of the Plasma Cell Disorders Program and director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute, of Atrium Health, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC
https://www.onclive.com/onclive-tv/dr-plimack-on-updated-findings-of-the-keynote426-study-in-rcc

May 31st, 2020 - Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology, at Fox Chase Cancer Center, discusses the updated findings from the phase 3 KEYNOTE-426 study in patients with previously untreated, advanced renal cell carcinoma (RCC).

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC
https://www.onclive.com/onclive-tv/dr-rodriguezabreu-on-the-final-analysis-of-the-keynote189-trial-in-nsclc

May 31st, 2020 - Delvys Rodriguez-Abreu, MD, medical oncologist at Hospital Universitario Insular de Gran Canaria in Gran Canaria, Spain, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer (NSCLC).

Promoting Health Equality and Nondiscrimination for Transgender and Gender-Diverse Youth.
https://doi.org/10.1016/j.jadohealth.2020.03.016
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine;

May 31st, 2020 - Adolescent and young adult health-care providers often care for transgender and gender-diverse (TGD) youth-youth whose gender identity is incongruent with the gender assigned to them at birth. This patient population faces health challenges distinct from their cisgender peers (i.e., youth whose gender identity aligns with their assigned gender at birth), which include the health impacts from ge...

Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice ...
https://doi.org/10.1016/j.prro.2020.04.002
Practical Radiation Oncology; Chino J, Annunziata CM et. al.

May 31st, 2020 - This guideline reviews the evidence and provides recommendations for the indications and appropriate techniques of radiation therapy (RT) in the treatment of nonmetastatic cervical cancer. The American Society for Radiation Oncology convened a task force to address 5 key questions focused on the use of RT in definitive and postoperative management of cervical cancer. These questions included th...

Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth.
https://doi.org/10.1016/j.jogc.2019.04.012
Journal of ObstEtrics and Gynaecology Canada : JOGC = Journal D'obstEtrique Et Gynecologie Du Canada : JOGC; Jain V, McDonald SD et. al.

May 31st, 2020 - To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes. To administer or withhold progesterone therapy for women deemed to be at high risk of SPB. Preterm birth, neonatal morbidity and mortality, and postnatal outcomes ...

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Locoregional Treatment of Intact Primary Tumor Does Not Improve Survival, HRQoL in Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200210/full/

May 30th, 2020 - Early initiation of locoregional treatment (LRT) of an intact primary tumor (IPT) in women with de novo stage IV metastatic breast cancer does not appear to prolong survival or improve health-related quality of life (HRQoL) compared with systemic therapy alone, according to a new study (Abstract LBA2). Seema A. Khan, MD, of the Northwestern Memorial Hospital, presented these findings during the...

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Axitinib prolongs PFS in metastatic adenoid cystic carcinoma
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/{40a4c150-78fc-4a61-ae96-5a8b84f9c6ee}/axitinib-prolongs-pfs-in-metastatic-adenoid-cystic-carcinoma

May 30th, 2020 - Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.